Published in Blood on December 01, 1988
Intermediate-dose melphalan for refractory myeloma. Blood (1989) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother (1995) 7.74
A modular set of lacZ fusion vectors for studying gene expression in Caenorhabditis elegans. Gene (1990) 5.27
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (1987) 4.02
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol (1994) 3.22
Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med (1984) 3.06
Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood (2000) 2.87
Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer (2001) 2.59
The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med (1998) 2.57
'A clinical trial to evaluate plaque removal with a double-headed toothbrush'. Br Dent J (1991) 2.57
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA (1969) 2.56
Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400. J Infect Dis (1978) 2.51
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood (1997) 2.13
Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer (2001) 2.08
Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys (1995) 2.05
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol (1999) 2.05
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood (1988) 1.95
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 1.89
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med (1982) 1.79
Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med (1994) 1.75
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71
Mantle-cell lymphoma. Lancet Oncol (2001) 1.70
Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol (2001) 1.65
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood (2001) 1.64
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol (1998) 1.64
Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (1988) 1.62
Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys (1998) 1.56
Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer (1983) 1.54
Primary plasma cell leukaemia. Br J Haematol (1994) 1.54
Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood (1998) 1.54
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood (1995) 1.52
2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood (1992) 1.52
Extraosseous multiple myeloma: imaging features. AJR Am J Roentgenol (1993) 1.52
Immunologic relationship between platelet membrane glycoprotein GPIIb/IIIa and cell surface molecules expressed by a variety of cells. Proc Natl Acad Sci U S A (1986) 1.48
Plasma cell granuloma of the nasal cavity treated by radiation therapy. Cancer (1991) 1.45
Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. J Urol (1995) 1.45
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood (1995) 1.45
Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol (1993) 1.44
Melphalan therapy for plasma cell myeloma. Blood (1968) 1.43
T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease. Am J Surg Pathol (1996) 1.42
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1990) 1.39
Children's magazines and science in the nineteenth century. Vic Period Rev (2001) 1.38
Estrogen receptor-alpha knockout mice exhibit resistance to the developmental effects of neonatal diethylstilbestrol exposure on the female reproductive tract. Dev Biol (2001) 1.37
Combination chemotherapy for multiple myeloma. Cancer (1972) 1.36
The novel metallothionein genes of Caenorhabditis elegans. Structural organization and inducible, cell-specific expression. J Biol Chem (1993) 1.35
Localized and indolent myeloma. Blood (1980) 1.33
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood (1986) 1.32
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med (1991) 1.32
High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med (1986) 1.31
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol (1995) 1.30
Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest (1985) 1.29
Prognostic factors in multiple myeloma. Cancer (1975) 1.29
Novel 5' exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma. Am J Pathol (1998) 1.29
Correlation of DNA distribution abnormalities with cytogenetic findings in human adult leukemia and lymphoma. Cancer Res (1977) 1.27
Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med (1990) 1.26
Plasma cell myeloma--new biological insights and advances in therapy. Blood (1989) 1.25
Homoharringtonine: history, current research, and future direction. Cancer (2001) 1.25
The growth fraction of human myeloma cells. Blood (1981) 1.24
Primary ovarian non-Hodgkin's lymphoma: outcome after treatment with combination chemotherapy. Gynecol Oncol (1997) 1.23
Unmaintained remissions in multiple myeloma. Blood (1978) 1.22
Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol (1997) 1.21
Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol (2001) 1.21
Curability of solitary bone plasmacytoma. J Clin Oncol (1992) 1.20
Both mosquito-derived xanthurenic acid and a host blood-derived factor regulate gametogenesis of Plasmodium in the midgut of the mosquito. Mol Biochem Parasitol (2001) 1.20
Richter's syndrome: a report on 39 patients. J Clin Oncol (1993) 1.19
CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant (2009) 1.19
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Hematology (2010) 1.18
Localized primary non-Hodgkin lymphoma of the breast. Am J Clin Oncol (1998) 1.18
Determination of ploidy and proliferative characteristics of human solid tumors by pulse cytophotometry. Cancer Res (1978) 1.18
High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med (1989) 1.18
Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer (1997) 1.17
Antibodies isolated by using cloned surface antigens recognize antigenically related components of Legionella pneumophila and other Legionella species. J Immunol (1986) 1.17
Nonsecretory multiple myeloma. Am J Hematol (1982) 1.17
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol (1990) 1.16
Ploidy and proliferative characteristics in monoclonal gammopathies. Blood (1982) 1.15
High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood (1987) 1.15
Molecular cloning and chemical synthesis of a region of platelet glycoprotein IIb involved in adhesive function. Proc Natl Acad Sci U S A (1987) 1.15
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology (2007) 1.14
Localized primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys (1997) 1.14
A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol (1989) 1.13
Prognostic features of asymptomatic multiple myeloma. Br J Haematol (1997) 1.13
Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol (2005) 1.13
Nephrotoxicity of combined cephalothin-gentamicin regimen. Arch Intern Med (1975) 1.12
Risk of disease progression in asymptomatic multiple myeloma. Am J Med (1993) 1.12
Plasma cell karyotype in multiple myeloma. Blood (1988) 1.11
Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies. Arch Pathol Lab Med (1999) 1.11
Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. J Clin Oncol (1995) 1.10
Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol (1997) 1.10